Compare IPCA Labs with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs AJANTA PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS AJANTA PHARMA IPCA LABS/
AJANTA PHARMA
 
P/E (TTM) x 23.2 28.5 81.6% View Chart
P/BV x 8.3 7.9 105.1% View Chart
Dividend Yield % 0.1 0.4 32.7%  

Financials

 IPCA LABS   AJANTA PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
AJANTA PHARMA
Mar-19
IPCA LABS/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0421,422 73.3%   
Low Rs590898 65.7%   
Sales per share (Unadj.) Rs298.6233.5 127.9%  
Earnings per share (Unadj.) Rs35.044.0 79.6%  
Cash flow per share (Unadj.) Rs49.452.2 94.8%  
Dividends per share (Unadj.) Rs3.009.00 33.3%  
Dividend yield (eoy) %0.40.8 47.4%  
Book value per share (Unadj.) Rs247.1255.1 96.9%  
Shares outstanding (eoy) m126.3588.02 143.5%   
Bonus/Rights/Conversions ESOSBB-  
Price / Sales ratio x2.75.0 55.0%   
Avg P/E ratio x23.326.4 88.4%  
P/CF ratio (eoy) x16.522.2 74.2%  
Price / Book Value ratio x3.34.5 72.6%  
Dividend payout %8.620.5 41.9%   
Avg Mkt Cap Rs m103,108102,081 101.0%   
No. of employees `00013.46.8 197.7%   
Total wages/salary Rs m7,8744,307 182.8%   
Avg. sales/employee Rs Th2,807.03,022.6 92.9%   
Avg. wages/employee Rs Th585.8633.4 92.5%   
Avg. net profit/employee Rs Th329.0569.1 57.8%   
INCOME DATA
Net Sales Rs m37,73220,554 183.6%  
Other income Rs m577211 273.6%   
Total revenues Rs m38,30920,765 184.5%   
Gross profit Rs m6,9015,664 121.8%  
Depreciation Rs m1,824721 253.1%   
Interest Rs m18912 1,626.7%   
Profit before tax Rs m5,4655,143 106.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0421,273 81.9%   
Profit after tax Rs m4,4223,870 114.3%  
Gross profit margin %18.327.6 66.4%  
Effective tax rate %19.124.8 77.1%   
Net profit margin %11.718.8 62.3%  
BALANCE SHEET DATA
Current assets Rs m23,77811,812 201.3%   
Current liabilities Rs m10,9753,776 290.6%   
Net working cap to sales %33.939.1 86.8%  
Current ratio x2.23.1 69.3%  
Inventory Days Days10477 134.1%  
Debtors Days Days6682 80.8%  
Net fixed assets Rs m20,36814,398 141.5%   
Share capital Rs m253175 144.1%   
"Free" reserves Rs m30,97122,277 139.0%   
Net worth Rs m31,22422,452 139.1%   
Long term debt Rs m1,4097 21,340.9%   
Total assets Rs m45,50726,962 168.8%  
Interest coverage x30.0444.3 6.7%   
Debt to equity ratio x00 15,345.6%  
Sales to assets ratio x0.80.8 108.8%   
Return on assets %10.114.4 70.4%  
Return on equity %14.217.2 82.2%  
Return on capital %17.323.0 75.5%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30810,682 162.0%   
Fx outflow Rs m6,2662,102 298.1%   
Net fx Rs m11,0428,580 128.7%   
CASH FLOW
From Operations Rs m4,9233,748 131.4%  
From Investments Rs m-1,563-2,228 70.2%  
From Financial Activity Rs m-1,832-1,475 124.2%  
Net Cashflow Rs m1,52845 3,379.9%  

Share Holding

Indian Promoters % 45.9 73.8 62.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 1.6 735.5%  
FIIs % 25.3 7.6 332.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 17.0 102.4%  
Shareholders   36,892 20,968 175.9%  
Pledged promoter(s) holding % 2.1 4.4 48.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DISHMAN PHARMA  CADILA HEALTHCARE  SUVEN LIFE SCIENCES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


May 7, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - BIOCON COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS